Impact of Timing of Concurrent Chemoradiation for Newly Diagnosed Glioblastoma: A Critical Review of Current Evidence

Seunggu J Han; Dario J Englot; Harjus Birk; Annette M Molinaro; Susan M Chang; Jennifer L Clarke; Michael D Prados; Jennie W Taylor; Mitchel S Berger; Nicholas A Butowski

doi:10.1227/NEU.0000000000000801

Impact of Timing of Concurrent Chemoradiation for Newly Diagnosed Glioblastoma: A Critical Review of Current Evidence

Neurosurgery. 2015 Aug;62 Suppl 1(Suppl 1):160-5. doi: 10.1227/NEU.0000000000000801.

Authors

Seunggu J Han¹, Dario J Englot, Harjus Birk, Annette M Molinaro, Susan M Chang, Jennifer L Clarke, Michael D Prados, Jennie W Taylor, Mitchel S Berger, Nicholas A Butowski

Affiliation

¹ *Department of Neurological Surgery, ‡Department of Epidemiology and Biostatistics, and §Department of Neurology, University of California, San Francisco, San Francisco, California.

Abstract

EORTC/NCIC, European Organisation for Research and Treatment of Cancer/National Cancer Institute of CanadaGBM, glioblastomaOS, overall survivalPFS, progression-free survivalSEER, Surveillance, Epidemiology, and End ResultsTMZ, temozolomide.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Brain Neoplasms / therapy*
Chemoradiotherapy / methods*
Glioblastoma / therapy*
Humans
United States

Grants and funding

F32 NS086353/NS/NINDS NIH HHS/United States